JAK-inhibition in Recurrent Classical Hodgkin Lymphoma (JeRiCHO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02164500
Recruitment Status : Recruiting
First Posted : June 16, 2014
Last Update Posted : March 22, 2018
Information provided by (Responsible Party):
Dr. Bastian von Tresckow, University of Cologne

Brief Summary:

The Purpose of this trial is:

  • to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL
  • to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Condition or disease Intervention/treatment Phase
Recurrent Classical Hodgkin Lymphoma Drug: Ruxolitinib Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 37 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Study Start Date : October 2015
Actual Primary Completion Date : March 2018
Estimated Study Completion Date : December 2018

Arm Intervention/treatment
Experimental: Ruxolitinib Drug: Ruxolitinib

Primary Outcome Measures :
  1. overall response rate [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • relapsed or refractory HL
  • ECOG <= 2,
  • no major organ dysfunction
  • written informed consent

Exclusion Criteria:

  • history of another primary malignancy ≤ 2 years
  • female patients who are pregnant or breast feeding
  • patients with a known history of HIV seropositivity
  • chronic active hepatitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02164500

Contact: Michael Fuchs

1st Dept. of Medicine, Cologne University Hospital Recruiting
Cologne, Germany, 50924
Contact: Michael Fuchs   
Sponsors and Collaborators
University of Cologne

Additional Information:
Responsible Party: Dr. Bastian von Tresckow, Dr., University of Cologne Identifier: NCT02164500     History of Changes
Other Study ID Numbers: JeRiCHO
First Posted: June 16, 2014    Key Record Dates
Last Update Posted: March 22, 2018
Last Verified: March 2018

Additional relevant MeSH terms:
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases